DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $231.56M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.14M
Average 0.24M
DBVT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
DBV Technologies S.A.NASDAQ: DBVT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 1668.2% from a year ago
Cash & equivalents stood at $229.2M at the end of Q1 FY2026, up 1668.2% from a year earlier and up 18.0% from the prior quarter. Over 3 fiscal years it compounded at -2.5% a year.
Context
- Cash & equivalents amounted to 86.0% of total assets at the end of Q1 FY2026, up 60.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +1668.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 194.17M USD
- Year-over-year change
- +498.2%
- 4-year CAGR
- +25.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 194.17M | +498.2% |
| FY2024 | 2024-12-31 | 32.46M | -77.0% |
| FY2023 | 2023-12-31 | 141.37M | -32.4% |
| FY2022 | 2022-12-31 | 209.19M | +170.6% |
| FY2021 | 2021-12-31 | 77.3M | — |
Cash & Equivalents vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's Mar 2026 cash & equivalents of $229.2M is the 3rd highest of the 11 companies compared; the peer median is $114.33M.
- Its year-over-year change of +1668.2% is the 2nd highest of 11, against a peer median of +72.2%.
- Cash & equivalents amounts to 86.0% of total assets for DBVT, versus a peer median of 31.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M | +2154.3% | +126.9% | 81.5% |
| Mar 2026 | $263.76M | +64.1% | +54.0% | 95.5% | |
| Mar 2026 | $229.2M | +1668.2% | -2.5% | 86.0% | |
| Mar 2026 | $177.91M | +742.2% | +47.1% | 85.3% | |
| Mar 2026 | $175.21M | +80.4% | +5.0% | 66.6% | |
| Mar 2026 | $131.06M | +9.7% | -14.7% | 20.3% | |
| Mar 2026 | $97.6M | +98.8% | -26.7% | 29.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $71.77M | +148.2% | -6.6% | 28.7% |
| Mar 2026 | $61.7M | -3.8% | -16.1% | 33.6% | |
| Mar 2026 | $35M | -72.6% | -10.9% | 12.1% | |
ENGNenGene Holdings Inc. | Apr 2026 | $29.83M | -48.2% | +442.5% | 9.7% |
| Peer median (excluding DBVT) | $114.33M | +72.2% | -0.8% | 31.3% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77.3M | 209.19M | 141.37M | 32.46M | 194.17M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 33.07M | 10.49M | 15.45M | 10.39M | 16.15M |
| Inventory | 0 | 2.68M | 0 | 0 | 0 |
| Other Current Assets | 0 | 1K | 0 | 0 | 0 |
| Total Current Assets | 114.52M | 223.07M | 158.92M | 44.39M | 212.94M |
| Property, Plant & Equipment (Net) | 24.92M | 17.61M | 17.93M | 16.81M | 14.95M |
| Goodwill | 0 | 661 | 0 | 0 | 0 |
| Intangible Assets | 22K | 9.34K | 58K | 40K | 22K |
| Long-term Investments | 3.97M | 1.66M | 3.68M | 4.31M | 620K |
| Tax Assets | 0 | (1.66M) | 0 | 0 | 0 |
| Other Non-current Assets | 2.9M | 5.83M | 2.4M | 111K | 5.19M |
| Total Non-current Assets | 31.81M | 23.44M | 24.07M | 21.27M | 20.78M |
| Total Assets | 146.32M | 246.52M | 182.99M | 65.66M | 233.72M |
| Account Payables | 11.43M | 14.47M | 23.3M | 22.03M | 40.94M |
| Short-term Debt | 3.51M | 1.13M | 883K | 846K | 16.27M |
| Tax Payables | 182K | 69K | 201.87K | 188K | 0 |
| Deferred Revenue | 4.15M | 2.14M | 0 | 0 | 0 |
| Other Current Liabilities | 12.13M | 9.82M | 11.79M | 7.42M | 217K |
| Total Current Liabilities | 31.4M | 29.52M | 37.34M | 31.14M | 58.03M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 8.75M | 21.42M | 934K | 838K | 1.51M |
| Total Non-current Liabilities | 15.9M | 22.54M | 5.46M | 7.14M | 6.92M |
| Total Liabilities | 47.29M | 52.07M | 42.8M | 38.27M | 64.95M |
| Common Stock | 6.54M | 10.72M | 10.97M | 11.65M | 26.08M |
| Retained Earnings | (98.05M) | (259.58M) | (238.86M) | (286.38M) | (393.13M) |
| Accumulated OCI | (15.4M) | (13.8M) | (8.13M) | (12.19M) | (5.43M) |
| Other Stockholders Equity | 6.14M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 99.03M | 194.45M | 140.19M | 27.39M | 168.77M |
| Total Debt | 10.66M | 4.15M | 6.55M | 7.8M | 21.68M |
| Net Debt | (66.64M) | (205.04M) | (134.81M) | (24.66M) | (172.48M) |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.